# GO-203-2C + Bortezomib For Relapsed Or Refractory MM

> **NCT02658396** · PHASE1 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** GO-203-2C
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02658396
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2019-05
- **Final completion:** 2022-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never open due to lack of funding
- **Last updated:** 2017-07-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658396, "GO-203-2C + Bortezomib For Relapsed Or Refractory MM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02658396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*